Hellow guys, Welcome to my website, and you are watching GI ASCO 2024 Highlights with Dr. Pamela Kunz – CheckMate 8HW, EMERALD-1, NETTER-2. and this vIdeo is uploaded by OncBrothers: Practice-Changing Cancer Discussions at 2024-02-01T15:00:27-08:00. We are pramote this video only for entertainment and educational perpose only. So, I hop you like our website.
| Name | GI ASCO 2024 Highlights with Dr. Pamela Kunz – CheckMate 8HW, EMERALD-1, NETTER-2 |
| Video Uploader | Video From OncBrothers: Practice-Changing Cancer Discussions |
| Upload Date | This Video Uploaded At 01-02-2024 18:00:27 |
| Video Discription | In discussion with Dr. Pamela Kunz, covering the Gastroenterology ASCO 2024 meeting highlights from Community Oncology perspective. We covered 3 important practice informing studies from GI ASCO with Dr. Kunz: - CheckMate 8HW: Nivolumab plus ipilimumab vs chemotherapy as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer - EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization - NETTER-2: [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors #GI #ASCO #HCC #Colon #Cancer #NET #Neuroendocrine #2024 #oncology #oncbrothers Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at [email protected] |
| Category | People & Blogs |
| Tags | cancer | oncology | chemotherapy | therapy | guidelines | nccn | summary | OncBrothers | brothers | Highlights | Onc | rohit | gosain | rahul | video | abtract | society | american | onc | doctor | dr. | healthcare | medicine | medical | oncbrothers | practice | changing | malignancy | malignant | chemo | prognosis | stage | tdxd | fda | approval | community | oncologist | oncoligists | chief | associate | ct | asco | esmo | keynote | pembrolizumab | gi | 2024 | emerald | nivolumab | ipilimumab | net | neuroendocrine | pamela | kunz | yale | hepatocellular | carcinoma | gastric | colon | msi | dmmr | lutetium | tace |
